India, Feb. 20 -- Immunic, Inc. (IMUX), Thursday reported positive data from phase 1b study of IMU-856 for the treatment of celiac disease, a chronic digestive and autoimmune disorder.
A post hoc analysis of patients treated with IMU-856 showed a dose-dependent increase of endogenous glucagon-like peptide-1 (GLP-1) levels.
"GLP-1, a hormone that occurs naturally in the gut, is released after eating and helps the body regulate blood sugar and satiety. It plays several critical roles, including triggering insulin release from the pancreas and blocking glucagon, a hormone raising blood sugar. Additionally, GLP-1 affects areas of the brain that process hunger and satiety," noted Hella Kohlhof, Chief Scientific Officer of Immunic.
IMU-856 als...